Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study by Bermejo-Pareja, Felix et al.
RESEARCH ARTICLE Open Access
Saliva levels of Abeta1-42 as potential biomarker
of Alzheimer’s disease: a pilot study
Felix Bermejo-Pareja
1,2, Desiree Antequera
2,3, Teo Vargas
2,3, Jose A Molina
1,2, Eva Carro
2,3*
Abstract
Background: Simple, non-invasive tests for early detection of degenerative dementia by use of biomarkers are
urgently required. However, up to the present, no validated extracerebral diagnostic markers for the early diagnosis
of Alzheimer disease (AD) are available. The clinical diagnosis of probable AD is made with around 90% accuracy
using modern clinical, neuropsychological and imaging methods. A biochemical marker that would support the
clinical diagnosis and distinguish AD from other causes of dementia would therefore be of great value as a
screening test. A total of 126 samples were obtained from subjects with AD, and age-sex-matched controls.
Additionally, 51 Parkinson’s disease (PD) patients were used as an example of another neurodegenerative disorder.
We analyzed saliva and plasma levels of b amyloid (Ab) using a highly sensitive ELISA kit.
Results: We found a small but statistically significant increase in saliva Ab42 levels in mild AD patients. In addition,
there were not differences in saliva concentration of Ab42 between patients with PD and healthy controls. Saliva
Ab40 expression was unchanged within all the studied sample. The association between saliva Ab42 levels and AD
was independent of established risk factors, including age or Apo E, but was dependent on sex and functional
capacity.
Conclusions: We suggest that saliva Ab42 levels could be considered a potential peripheral marker of AD and help
discrimination from other types of neurodegenerative disorders. We propose a new and promising biomarker for
early AD.
Background
With increasing life expectancy across the world, Alzhei-
mer’s disease (AD), the most common cause of demen-
tia, is a rapidly growing socioeconomic and medical
problem. AD diagnosis is time consuming and requires
a combination of clinical assessment, psychological test-
ing, imaging and exclusion of other neurological disor-
ders. In light of these facts, a molecular biomarker that
could identify and classify AD would be particularly use-
ful in order to confirm the diagnosis, to perform epide-
miological screening, to identify distinct groups of
patients, to predict the outcome of the disease, and to
monitor its progression and its sensitivity to treatment.
In fact, lack of tools to detect preclinical AD has been
suggested to be one of the main obstacles for the devel-
opment of new treatments [1]. The ideal biomarker for
AD should detect a fundamental feature of neuropathol-
ogy: it should be as sensitive and specific as the clinical
diagnosis, reliable, reproducible, simple to perform,
inexpensive and non-invasive (studies on blood, urine,
saliva, or buccal scrapings). Moderately invasive tests
(skin, rectal biopsies, bone marrow samples, or cere-
brospinal fluid -CSF-) or cerebral biopsy, are inconveni-
ent for routine clinical practice.
In humans, in addition to the classical accumulation
in the brain, amyloid-beta protein (Ab)d e p o s i t sa r e
found in peripheral regions, including skin [2], nasal
mucosa [3], and the lacrimal [4], and lingual glands [5].
The use of human salivary gland biopsies has been
recently described as a tool for research on familial amy-
loidotic polyneuropathy (FAD) [6], and on AD [7]
because both amyloid precursor protein (APP) and Ab
are expressed in human salivary epithelial cells [7]. Sal-
iva is produced from salivary glands and mucous mem-
branes and, as a biological fluid, is simple to obtain.
Additionally, salivary levels may reflect changes in CSF
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levels of salivary acetylcholinesterase (AChE) with AD
[9]. These findings may prove to be a useful marker of
central cholinergic activity which is a key event in the
biochemistry of AD.
The majority of the studies of accepted AD biomar-
kers to date have been carried out using samples of CSF
obtained by lumbar puncture [10]. This is an invasive
procedure that is particularly unpleasant for the subject
and for which explicit consent is required. Recently, it
has been shown that identification of blood biomarkers
may allow the development of tests for AD [11,12]. In
this study, we report that significant and reproducible
levels of salivary Ab42 can be detected in subjects and
there is a specific correlation with development of AD
pathology.
Methods
Subjects
The study included three groups: (1) 70 Alzheimer’s dis-
ease (AD); (2) 56 elderly nondemented controls without
neurological disease or cognitive impairment; and (3) 51
Parkinson’s disease (PD) patients. All AD cases included
in these series were diagnosed with dementia according
to the Diagnostic and Statistical Manual of Mental Dis-
orders (DSM)-IV criteria [13], and NINCDS-ADRDA
criteria [14], and diagnosis required evidence of cogni-
tive decline, (neuropsychological test battery, clinical
mental examination) as well as evidence of impairment
in social or occupational function. The mini-mental
state examination (MMSE) was used to assess cognitive
function [15]. The mean value of MMSE score for the
AD patients was 17. All cases had an extensive bio-
chemical measurement including levels of vitamin B12
and folate and thyroid hormones and neuroimaging
techniques (brain MRI and/or CT scan). Classification
of mild, moderate and severe degrees of AD was per-
formed, and the diagnosis of vascular dementia was
excluded in all cases, using DSM-III-R criteria. The con-
trol group was formed of family members or caregivers
of the AD patients, who all had a clinical interview with
a senior neurologist that showed a completely normal
cognitive and functional level. No formal neuropsycho-
logical battery was performed in this group. PD group
was formed of patients who had been diagnosed under
the criteria of probable PD [16,17]. Demographic and
health characteristics of the final sample (n = 136) are
presented (table 1).
Saliva and blood collection
This study was approved by the Ethic Committee of Clin-
ical Investigation of the Hospital ‘12 de Octubre’.
Informed consent from all subjects was obtained prior to
their participation Saliva samples were obtained from
both healthy volunteers and patients with AD and PD
and the study was carried out with full ethical permis-
sion. Saliva samples were collected in sterile plastic con-
tainers previously treated with 2% sodium azide solution,
a concentration which has been shown to be sufficient to
prevent microbial decomposition of saliva [18]. Partici-
pants were asked to wait at least 4 hours after eating or
drinking (initiated at approximately the same time for
each participant (13:00 hours), before providing saliva
samples of approximately 1 ml into the containers, and
these were centrifuged at 1500 rpm for 5 minutes to
remove debris, in a similar manner to that previously
described [19]. Then, the samples were immediately fro-
zen at -80°C until used. Blood samples were obtained
through antecubital vein puncture. Blood was centrifuged
at 2500 rpm for 10 minutes, and plasma was collected,
aliquoted and immediately frozen at -80°C. Cellular frac-
tion was used for DNA extraction and genotyping assays.
Apo E genotyping
Apo E genotypes of AD and control subjects were deter-
mined by established methods as described previously
[20]. Genomic DNA was extracted from peripheral
blood using Illustra™ blood genomicPrep Mini Spin Kit
(GE Healthcare). Apo E genotyping (ε2/ε3/ε4 isoforms)
was performed using FRET probes.
Immunoassays
30 μl of saliva sample was mixed with an equal volume
of 2× SDS sample buffer and denatured by heating at
95°C for 5 minutes. All samples were resolved by 10%
SDS-polyacrylamide gel electrophoresis and transferred
to nitrocellulose membranes (Bio-Rad) by electroblotting
as previously described [21]. The following antibodies
were used: mouse monoclonal anti-gelsolin (Sigma-
Aldrich), rabbit polyclonal anti-TTR (Santa Cruz Bio-
technology), goat anti-mouse HRP-conjugated (Bio-Rad),
and goat anti-rabbit HRP-conjugated (Bio-Rad). Peroxi-
dase-labeled lectin (Sigma) was used as gel loading con-
trol. Densitometric analysis was performed using ImageJ
software (NIH Image).
Table 1 Demographic and health characteristics of the
final sample (n = 136)
Mean age Sex
Men/
Women
Mean
MMSE
(range)
Mean
onset
(range)
AD patients 77.20 (60-
91)
21/49 17 (4-28) 2.56 (0-12)
PD patients 72.96 (60-
93)
26/25 28 (22-30) 3.8 (1-5)
Control
subjects
74.35 (64-
85)
17/39 nd
MMSE = mini-mental state examination; AD = Alzheimer’s disease; PD =
Parkinson’s disease; nd = not determined.
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and human plasma samples were determined with
human specific enzyme-linked immunosorbent assay
(ELISA) (Biosource International, Invitrogen), according
to the manufacturer’s instructions and as previously
described [22]. 50 μl of saliva and plasma samples were
added in duplicate to the microtiter wells. Detection
limit of the assay was 6 pg/ml for Ab40 and 1 pg/ml for
Ab42.
Previous to the immunoassays, protein concentration
was assessed using a Spectrophotometer NanoDrop ND-
1000, to normalize sample protein levels.
Statistical analysis
Data were analysed with SPSS for Windows (version
15.0). To compare demographic, clinical, and saliva and
plasma data between groups, we used ANOVA followed
by a Tuckey-Kramer test, and Mann-Whitney U-test
analysis when appropriate. The differences were consid-
ered to be significant at p < 0.05. The Spearman rank
correlation was used for correlation analyses.
Results
177 patients with AD, PD and aged controls were
assessed, and Ab40 and Ab42 levels were measured in
saliva from these patients using a sensitive and specific
Ab ELISA. It is particularly relevant that we were able
to detect Ab40 and Ab42 i nh u m a ns a l i v ab yas i m p l e
and reproducible method. The groups did not differ sig-
nificantly by age or sex. Our findings show that saliva
concentration of Ab42 has a tendency to increase in AD
patients compared with PD and control groups, but this
effect was not statistically significant. Interestingly, when
we analyzed the three categories of AD patients, we
found that saliva Ab42 levels were significantly increased
in the first category of AD patients [in mild AD stage (p
= 0.043, and table 2)], whereas saliva Ab42 levels in
moderate AD stage are also increased but with a high
standard deviation (SD). Interestingly, the third category
of AD, the severe AD stage, has similar than those
observed in control group (table 2). Age range was simi-
lar between all AD stages and the control group. A 2 ×
2 contingency table analysis, with a cut-off = 7.85 pg/
ml, allowed the calculation of sensitivity and specificity
(defined as the proportion of true positive and the por-
tion of true negative that are correctly identified by the
test, respectively). The results were 16% and 93%,
respectively. In addition, we performed ROC curve ana-
lysis, with 0.547 (area under the curve) AUC (95% CI
0.4-0.68). On the other hand, Ab40 was unchanged
between AD patients and healthy subjects (table 2). We
also analyzed the ratio between saliva Ab42 and Ab40
and we found that this ratio was higher, but not statisti-
cally significant (p = 0.2), in mild and moderate AD
patients (0.35 and 0.54, respectively) in compared with
control subject (0.13), whereas it was unchanged in
severe AD patients (0.12).
Overall, saliva Ab42 levels were not significantly higher
with age
However, comparison of AD patients aged 60-65 with
those aged 66-70 showed highly significant elevation in
saliva Ab42 levels (1.64 ± 0.44 pg/ml versus 6.46 ± 3.43
pg/ml, p = 0.016).
In addition, plasma levels of Ab40 and Ab42 did not
differ significantly between patients with AD and control
subjects (259 ± 91.9 pg/ml versus 225.1 ± 77.3 pg/ml,
and 42.4 ± 92.7 pg/ml versus 52.4 ± 68.9 pg/ml, respec-
tively), in accordance with recent studies [23]. Spearman
rank analysis of plasma and saliva levels was not signifi-
cant for either Ab40 or Ab42 levels.
To determine whether the elevated saliva Ab42 was
associated with the Apo E ε4 allele, all subjects were
genotyped for ApoE and their Ab42 levels were analyzed
according to the ApoE genotypes. The Apo E ε4a l l e l e
frequencies were 45% (15 with Apo E ε3/4 genotype and
3w i t hA p oEε4/4 genotype) in the AD group and 12%
(3 with Apo E ε3 / 4g e n o t y p ea n d1w i t hA p oEε2/4
genotype) in the control group. Firstly, we found that
ApoE genotype correlates with AD onset (Spearman
rank correlation R = 0.428, p = 0.001). Levels of Ab42
were higher, but not statistically significantly, in patients
with AD and without the Apo E ε4 allele than in those
Table 2 Saliva Ab42 levels in patients with
neurodegenerative diseases and control subjects
Group Ab42 (pg/ml) Ab40 (pg/ml) No. of subjects
AD patients 6.81 ± 20.04 22.3 ± 4.88 70
Mild 7.67 ± 16.25* 21.87 ± 5.7 29
Moderate 11.70 ± 34.76 21.5 ± 4.17 24
Severe 3.03 ± 3.49 23.92 ± 4.55 17
PD patients 3.66 ± 4.21 26.41 ± 5.12 51
Control subjects 2.89 ± 4.96 20.82 ± 5.55 56
AD = Alzheimer’s disease; PD = Parkinson’s disease. Values are mean ± SD. *p
< 0.05 versus control subjects
Table 3 Saliva Ab42 levels in patients with AD and
control subjects
Group No. Of subjects Age Ab42 (pg/ml)
AD patients 38
With Apo E ε4 18 75.18 ± 7.91 6.42 ± 15.48
Without Apo E ε4 20 75.05 ± 8.85 12.52 ± 33.58
Control subjects 34
With Apo E ε4 4 68.5 ± 8.70 2.05 ± 1.48
Without Apo E ε4 30 69.10 ± 9.25 2.51 ± 2.61
Data are mean ± SD; AD = Alzheimer’s disease.
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controls with and without Apo E ε4 allele (table 3).
To test that protein changes are specific to Ab42
levels, we measured protein concentration in saliva sam-
ples from all experimental groups. We did not find sig-
nificant differences between groups (6.39 ± 3.68 ng/μli n
aged subjects, 6.49 ± 4.79 ng/μl in AD patients, and
6.67 ± 5.71 ng/μl in PD patients, data are expressed as
mean ± SEM). Additionally, we tested others protein
concentrations in these saliva samples. We choose two
proteins with Ab-carrier function, gelsolin, and trans-
thyretin. Using Western-blot assays, we did not observe
an alteration in gelsolin (figure 1a) and transthyretin
(figure 1b) expression in AD patients compared with
control subjects. These results support our finding in
human saliva that Ab42 levels are closely associated with
AD diagnosis.
Demographic risk factors could modify the association
between pathological saliva Ab42 and progression to AD.
One of the studied variables was MMSE score. Mean
MMSE score of AD patients was 17 (range 4-28) (table
1), and correlates with the three categories of AD
(Spearman rank correlation R = -0.763, p = 0.001). The
relationship between these variables was similar for
males or females. Other studied risk factors in the AD
group were: hypertension (with a prevalence of 47.1%),
hypercholesterol (10%), arthritis (20%), depression
(20%), diabetes (12.9%), and heart disease (15.7%). We
analyzed whether there was an association between
these risk factors and saliva Ab42 levels. With Mann-
Whitney U-test analysis, we found that the concentra-
tion of saliva Ab42 correlates with sex (95% CI 0.71-
2.29, p = 0.002) in the AD group.
Discussion
Early diagnosis of AD represents a primary goal, and
the role of biomarkers seems to be crucial in a rou-
tine clinical setting. The main findings of this study
are that saliva Ab42 levels are significantly elevated in
early stage AD patients in comparison to control sub-
jects, and we suggest that this effect is specific to AD
and not to other neurodegenerative disorders, includ-
ing PD. These data result in a slightly higher specifi-
city, and suggest that measuring saliva Ab42 may be
used as biomarker to identify and confirm early AD
diagnosis.
Figure 1 Western-blot analysis of saliva levels of gelsolin (a) and transthyretin (b) in AD and control groups (n = 41-44 per group).
Figures shows representative blots and quantitative from 4 independent measurements.
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sensitivity and specificity and to monitor the biological
activity of AD in terms of the burden of neuronal invol-
vement and the rate of disease progression. They must
initially supplement our more traditional neuropsycholo-
gical and imaging markers and may progress to provide
useful tool to test the pharmacological action of anti-
dementia compounds [24,25]. The currently best vali-
dated CSF biomarkers, pTau and Ab42, with a reported
sensitivity and specificity of around 90-95% for the diag-
nosis of AD, show generally a good correlation with cer-
ebral tau and Ab pathology [26-28]. As biomarkers in
plasma several substances have been examined, but
none of these markers had enough sensitivity or specifi-
city to diagnose AD [24].
S a l i v ai sf r e q u e n t l yu s e dt ot e s tf o rt h el e v e l so fa
number of hormones, and is considered as a non-inva-
sive technique [29]. Therefore, the identification of
robust and reproducible Ab42 expression in saliva is of
particular importance as it may serve as a potential indi-
cator of AD neuropathology that can be measured with
the minimum of stress for the subject. The mechanism
by which Ab42 accumulates in saliva is unclear. This
localization could result from release of this peptide
from salivary glands by APP processing as a conse-
quence of secretase enzymes action in salivary epithelial
cells [7]. Our data could reflect a similar situation to
brain Ab generation. The vast majority of studies per-
formed so far have reported an increased accumulation
of Ab42 in cerebral parenchyma, mainly as senile pla-
ques [30], whereas Ab42 levels were reduced in CSF of
patients with AD [31,32]. Thes i g n i f i c a n c eo fs a l i v aA b
levels in relation to Ab accumulation in the brain is
unknown; however, their concentrations are comparable
with those observed from tissues other than brain,
including lens [33]. Lower levels of CSF Ab42 in the AD
group may be explained due to loss of neurons that pro-
duce the APP, brain Ab accumulation, and/or decreased
Ab clearance, as a consequence of impaired blood-brain
barrier. As, the latter is not present in salivary glands,
Ab produced from APP glands may be delivered and
accumulated in the saliva, mainly in mild AD patients,
whereas, in severe AD stage, saliva Ab42 levels return to
control values. This pattern may reflect a parallelism
with CSF Ab42 levels. The association of different com-
binations of saliva Ab levels with AD was independent
of established risk factors such as age or Apo E geno-
type, major risk factors for sporadic AD. However, we
found a significant correlation between sex and saliva
Ab42 levels in patients with AD. With several discrepan-
cies, our data are consistent with previous studies using
CSF and plasma samples [27,34]. Several studies had
described no correlation between CSF Ab levels and
dementia severity [27,34-36]. However, others showed
weak [37], or strong [38] correlation between these vari-
ables. In our study, we showed no significant relation-
ship between saliva Ab42 levels and MMSE scores,
however when we analyzed the three categories of AD
patients, accordingly with the functional capacity, we
found a significant correlation. Thus, large and longitu-
dinal studies with a greater number of samples will be
necessary to determine conclusively whether there is a
relationship between saliva Ab42 levels and progression
of AD.
Decreased saliva production is common amongst
elderly people, and in patients with AD, salivary flow
from the submandibular gland has been found to be sig-
nificantly impaired [39]. However, the protein concen-
tration of the saliva samples obtained from the elderly
control subjects was similar to those of the subjects
either with AD or PD. Additionally, we decided to inves-
tigate whether the concentration of other proteins may
be changed in saliva samples from AD patients. Ab
forms complexes with protein carriers, including trans-
thyretin or gelsolin, to prevent peptide polymerization
and aggregation [40-42]. Since these proteins are present
in body fluids [32,43], and are significantly reduced in
CSF from AD patients [32,44,45], we chose them to test
our hypothesis. Since total protein concentration was
similar in AD patients and healthy subjects, and these
secreted proteins was unchanged in both groups, we
may suggest that elevated Ab42 levels represent a speci-
fic change for AD, and can not be attributed to a gen-
eral increase in salivary protein concentration.
As usual, there were various difficulties in the mea-
surement of Ab levels in body fluids. Additionally, Ab
values decreased over time, even if the samples were
frozen [46]. Although range of saliva Ab42 levels was
high, we consider that is not in discrepancy with those
reported in plasma or CSF samples from AD patients,
with range seen from 100 pg/ml to 770 pg/ml, and 25
pg/ml to 325 pg/ml, respectively [34]. In this study, we
demonstrate the remarkable reproducibility of the saliva
Ab ELISA in different series of repetitive measurements.
It is particularly significant that saliva analyses of Ab42
are increased in mild AD patients, whereas in the severe
stage, associated with a greater neurodegeneration, the
levels are unchanged. Our data was supported by the
ratio Ab42 /Ab40 in saliva that was higher in mild and
moderate AD patients in compared with control subject,
whereas it was unchanged in severe AD patients. This
fact is consistent with the main objective of AD biomar-
kers: the early diagnosis. Indeed, further studies will be
performed to determine saliva Ab42 levels in mild cogni-
tive impairment (MCI), an intermediate stage to demen-
tia, how these levels change across the transition from
normal to MCI, and the interactions with age and Apo
E genotype. If validated in other consecutive studies
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Page 5 of 7with long follow-up and large number of patients, these
results may have an effect on diagnosis and on the
design of clinical trials of patients with mild AD.
Conclusions
There were no significant differences in Ab42 levels
between AD, PD and controls subjects. However, our
findings show that saliva concentration of Ab42 differs
between mild AD and non-demented control subjects,
and that this is a specific characteristic of AD, being
absent in PD. To our knowledge, no study to date has
investigated the possibility of overlapping AD-associated
Ab levels in saliva and brain of subjects with this disor-
der. Our results show that saliva analyses of Ab42 are
powerful risk markers for development of clinical AD in
patients.
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